# Nocardia rubra cell wall skeleton-induced MARCO expression: implications for improved phagocytosis and cytokine secretion in tumor-associated macrophages

**Authors:** Guiyuan Zhou, Wei Chen, Xiaomin Dong, Qianyu Guo, Xue Bai, Yan Zheng, Lei Zhang, Suxia Shao

PMC · DOI: 10.3389/fimmu.2026.1611476 · Frontiers in Immunology · 2026-02-12

## TL;DR

This study shows that Nocardia rubra cell wall skeleton boosts immune function in tumor-associated macrophages by increasing MARCO expression, improving phagocytosis and cytokine production.

## Contribution

The study identifies MARCO as a novel mediator of Nr-CWS-induced macrophage reprogramming in HPV-related neoplasia.

## Key findings

- Nr-CWS upregulates MARCO expression in TAMs, enhancing phagocytic activity and proinflammatory cytokine secretion.
- MARCO expression is significantly altered in most tumor tissues and correlates with immune cell infiltration.
- MARCO inhibition suppresses Nr-CWS-induced immune functions in TAMs.

## Abstract

Nocardia rubra cell wall skeleton (Nr-CWS) demonstrates a significant therapeutic effect against human papillomavirus (HPV) infection, but its precise immunomodulatory mechanisms warrant further investigation. This study investigates how Nr-CWS influences tumor-associated macrophages (TAMs) immune functions through macrophage receptor with collagenous structure (MARCO)-mediated mechanisms.

Cervical tissues of three cervical intraepithelial neoplasia (CIN) patients receiving Nr-CWS monotherapy and HPV infection turning negative were collected before and after treatment, and gene microarray analysis was performed. MARCO expression and immune cell infiltration were further analyzed using transcriptomic data from 33 tumor types in The Cancer Genome Atlas (TCGA). In vitro, TAMs derived from Human Monocytic Leukemia Cell Line 1 (THP-1) cells were treated with Nr-CWS, and changes in MARCO expression, cytoskeletal rearrangement, pseudopod length, lysosome count, and cytokine secretion were assessed. MARCO inhibition experiments were also performed.

Gene microarray revealed significant upregulation of MARCO, a key phagosome pathway gene, post-treatment. TCGA analysis indicated that MARCO expression is significantly altered in most tumor tissues compared to normal tissues and is associated with the infiltration of multiple immune cell types, with a particularly strong correlation to macrophage abundance. Histologically, Nr-CWS increased MARCO⁺ macrophages in cervical tissues. In vitro, Nr-CWS elevated MARCO expression in TAMs, enhanced pseudopod formation, lysosome number, cytoskeleton reorganization, and promoted proinflammatory cytokine secretion. Conversely, MARCO inhibition suppressed these immune functions.

The study demonstrates that Nr-CWS enhances TAM anti-tumor immune function via MARCO upregulation, leading to improved phagocytic activity and proinflammatory response. These findings align with genomic and cellular evidence, suggesting MARCO as a key mediator in Nr-CWS-induced macrophage reprogramming, with implications for HPV-related neoplasia immunotherapy.

## Linked entities

- **Genes:** MARCO (macrophage receptor with collagenous structure) [NCBI Gene 8685]
- **Diseases:** human papillomavirus infection (MONDO:0005161), cervical intraepithelial neoplasia (MONDO:0022394)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** Myd88 (myeloid differentiation primary response gene 88) [NCBI Gene 17874], CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, Cd68 (CD68 antigen) [NCBI Gene 12514] {aka Lamp4, Scard1, gp110}, Cd86 (CD86 antigen) [NCBI Gene 12524] {aka B7, B7-2, B7.2, B70, CLS1, Cd28l2}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, TLR2 (toll like receptor 2) [NCBI Gene 7097] {aka CD282, TIL4}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, nr (nervous) [NCBI Gene 18170], Cd163 (CD163 antigen) [NCBI Gene 93671] {aka CD163v2, CD163v3}, MARCO (macrophage receptor with collagenous structure) [NCBI Gene 8685] {aka SCARA2, SR-A6}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, Marco (macrophage receptor with collagenous structure) [NCBI Gene 17167] {aka Ly112, Scara2}, Tlr2 (toll-like receptor 2) [NCBI Gene 24088] {aka Ly105}, CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}
- **Diseases:** CESC (MESH:D002294), cervical cytological abnormalities (MESH:D002575), HPV (MESH:D030361), Set (MESH:D020920), CHOL (MESH:D018281), LUAD (MESH:D000077192), CIN (MESH:D002578), cancers (MESH:D009369), endocervical adenocarcinoma (MESH:D000230), Cervical cancer (MESH:D002583), inflammation (MESH:D007249), KIRC (MESH:D002292), BLCA (MESH:D001749), LIHC (MESH:D006528), TAMs (MESH:D000072716), PCPG (MESH:D010673), necrotic (MESH:D009336), Monocytic Leukemia Cell Line 1 (MESH:D015458), SKCM (MESH:C562393), breast cancer (MESH:D001943), carcinogenic infection (MESH:D007239), HR (MESH:D002303), cervical precancerous lesions (MESH:D011230), THCA (MESH:D013964), tumorigenic (MESH:D002471)
- **Chemicals:** oligonucleotides (MESH:D009841), biotin (MESH:D001710), CFDA-SE (MESH:C087165), SDS (MESH:D012967), Neutral Red (MESH:D009499), Triton X-100 (MESH:D017830), polyacrylamide (MESH:C016679), streptomycin (MESH:D013307), PMA (MESH:D013755), PAM (MESH:C028797), phalloidin (MESH:D010590), Paraffin (MESH:D010232), gold (MESH:D006046), Trypan blue (MESH:D014343), 4',6-Diamidino-2'-phenylindole (MESH:C007293), DMSO (MESH:D004121), formaldehyde (MESH:D005557), Nr (MESH:C018613), calcium (MESH:D002118), eosin (MESH:D004801), Carboxyfluorescein diacetate (MESH:C027780), glutaraldehyde (MESH:D005976), polyvinyl difluoride (MESH:C024865), alcohol (MESH:D000438), TAK-242 (MESH:C507035), paraformaldehyde (MESH:C003043), CO2 (MESH:D002245), tert-butanol (MESH:D020002), fluorescein (MESH:D019793), arabinogalactan (MESH:C005653), hematoxylin (MESH:D006416), penicillin (MESH:D010406), LysoTracker (MESH:C493330), DND-99 (-), H&amp;E (MESH:D006371), dextran (MESH:D003911)
- **Species:** Human papillomavirus (species) [taxon 10566], Rhodococcus ruber (species) [taxon 1830], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12936005/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12936005/full.md

## References

68 references — full list in the complete paper: https://tomesphere.com/paper/PMC12936005/full.md

---
Source: https://tomesphere.com/paper/PMC12936005